Breeding
Managing extended lactation production Pages 20-21 August 2023
Volume 70 Issue 8
YOUNGSTOCK
Take the next step with Mastitis Vaccination
Coronavirus, pneumonia and rearing protocols
Ask your vet about your mastitis prevention plan
2,5% Bacillus 2,7% Coryne. bovis 4,4% Strep. dysgalactiae
3,6% Others
Pages 32-50 0,9% Klebsiella spp
28,2% E. coli
HOUSING & SLURRY 11% Staph. aureus
Storage solutions and the value of cow space Pages 52-70
35,9% S. uberis
11% Non-aureus Staph
Andrew Biggs BVSc, FRCVS and Vale Veterinary Laboratory Data. Primary pathogen identified in all high SCC and clinical mastitis milk samples from 2019-2021. STARTVAC® Inactivated vaccine, Bovine mastitis, in injectable emulsion. COMPOSITION PER DOSE (2 ML): Inactivated Escherichia coli (J5) 50 RED60*; Inactivated Staphylococcus aureus (CP8) SP 140strain expressing SAAC** 50 RED80***. Adjuvant. * RED60: Rabbit effective dose in 60% of the animals (serology). **SAAC: Slime Associated Antigenic Complex. ***RED80: Rabbit effective dose in 80% of the animals (serology). INDICATIONS: Cows and Heifers: To prevent Mastitis. For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulasenegative staphylococci.The full immunisation scheme induces immunity from aproximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days postparturition). Further information available from the SPC or on www.hipra.com. For more information about side-effects, precautions, warnings and contraindications please refer to the SPC, the packaging or product leaflet. LEGAL CATEGORY: POM-V- Veterinary medicinal product under veterinary prescription. MARKETING AUTHORISATION HOLDER: Laboratorios Hipra, S.A. la Selva, 135, 17170-AMER (Girona) SPAIN. MARKETING AUTHORISATION NUMBERS: UK(GB): Vm17533/5010, UK(NI): EU/2/08/092/003-6. Use Medicines Responsibly. UBAC®, emulsion for injection for cattle. COMPOSITION PER DOSE: Lipoteichoic acid (LTA) from Biofilm Adhesion Component (BAC) of Streptococcus uberis, strain 5616 ≥ 1 RPU. Montanide ISA 907.1 mg. Monophosphoryl Lipid A (MPLA). INDICATIONS: For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in Streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by Streptococcus uberis intramammary infections. Further information available from the SPC or on www.hipra.com. For more information about side-effects, precautions, warnings and contra-indications please refer to the SPC, the packaging or product leaflet. LEGAL CATEGORY: POMV- Veterinary medicinal product under veterinary prescription. MARKETING AUTHORISATION HOLDER: LABORATORIOS HIPRA S.A. Avda. la Selva 135. 17170 Amer (Girona) Spain. MARKETING AUTHORISATION NUMBERS: UK(GB): Vm17533/5011, UK(NI): EU/2/18/227/001-004. Use Medicines Responsibly. These products are not licensed for concurrent use. A decision to use either of these vaccines before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis. HIPRA UK and IRELAND Foxhall Business Centre, Foxhall Lodge, Foxhall Road, Nottingham, NG7 6LH. United Kingdom Tel.: (+44) 0115 845 6486 · ukandireland@hipra.com · www.hipra.com
MACHINERY
JCB J403E electric loader put through its paces Pages 72-74
MILK PRICES Pages 76-78
TIP OF THE MONTH: Study the credentials of methane inhibitors – p14
DF Aug p1 Cover MB KJ.indd 1
13/07/2023 14:07